MINNEAPOLIS & ST. PAUL, Minn.--(BUSINESS WIRE)--
(NASDAQ: CLXT) a consumer-centric, food- and agriculture-focused Company, announced today the hiring of William F. (Bill) Koschak, as Chief Financial Officer of Calyxt, effective January 7, 2019. Mr. Koschak will be assuming the responsibilities of current interim CFO, Eric Dutang, who remains CFO of Cellectis, Calyxt’s parent company.
“Bill’s impressive professional background, especially his extensive experience in the consumer packaged goods and food service industries brings a unique combination of skills that will be crucial to the team as we advance towards commercialization of our first food ingredient, our high-oleic soybean oil,” said Jim Blome, Calyxt CEO. “We look forward to working with Bill as we move into a new and exciting year for Calyxt, and continue towards our mission to make the food Americans love a healthier choice.”
Mr. Koschak brings over 25 years of corporate, finance and accounting leadership to Calyxt, having spent most of the last ten years as an operating or corporate CFO. Most recently, Mr. Koschak was Vice President, Finance for the Brain Therapies business unit of Medtronic (NYSE: MDT) and also served as Interim Vice President, General Manager, for one of the units of Brain Therapies for several months. Prior to Medtronic, Mr. Koschak also held executive positions at Young America Holdings, where he was CFO, General Mills (NYSE:GIS), and KPMG LLP. For the majority of his 10 years with General Mills, he was Vice President, Finance for the Convenience Stores & Foodservice segment. He was a partner at KPMG where he focused on complex financial matters and financial trading, investment banking and lending businesses. In his varied roles across industries, Mr. Koschak gained deep financial expertise and experience in corporate and operating finance roles, capital markets, M&A, and business strategy. He was recognized as a CFO of the Year by the Twin Cities Business Journal in 2016 and currently serves on the board of 1st Financial Bank USA.
“I am thrilled to be joining Calyxt at such an important phase in its growth,” commented Bill Koschak. “Calyxt has been leading the way with its innovative approach to create healthier food ingredients, and now the company is on the cusp of commercializing the world’s first gene-edited product to benefit consumers. I’m excited to begin working with the team to help them capitalize on this important moment in agricultural and food history.”
About Calyxt
Calyxt, Inc. is a consumer-centric, food- and agriculture-focused company. Calyxt is pioneering a paradigm shift to deliver healthier food ingredients, such as healthier oils and high fiber wheat, for consumers and crop traits that benefit the environment and reduce pesticide applications, such as disease tolerance, for farmers. Calyxt develops non-transgenic crops leveraging processes that occur in nature by combining its leading gene-editing technology and technical expertise with its innovative commercial strategy. Calyxt is located in Minneapolis-St. Paul, Minn., and is listed on the Nasdaq market (ticker: CLXT).
For further information please visit our website:
Calyxt™ and the corporate logo are trademarks owned by Calyxt, Inc.
TALEN® is a registered trademark owned by the Cellectis S.A.
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, our anticipated growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including those factors discussed under the caption entitled “Risk Factors” in Calyxt’s Annual Report on Form 10-K, and Cellectis’ Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2017 along with other Calyxt and Cellectis subsequent filings with the U.S. Securities and Exchange Commission. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by applicable laws.
View source version on businesswire.com:
